Sanity Group GmbH

Based in Germany, Sanity Group GmbH operates in the cannabis industry, focusing on the regulated distribution of cannabinoid products for medical and recreational use through licensed dispensaries. Sanity Group GmbH specializes in the cannabis sector, aiming to facilitate both medical and recreational cannabis access. In March 2026, Organigram Global will acquire Sanity Group GmbH from HV Capital, Hillcrest Venture Partners, Redalpine, German Media Pool, Cherry Ventures, Atlantic Labs, Casa Verde Capital, Calyx Capital Partners, Navy Capital, TQ Ventures, SOJE Capital, and Bitburger Ventures. Financial terms were not disclosed.

Finn Hänsel, the founder, has a background in entrepreneurship, although specific previous ventures are not mentioned. Sanity Group GmbH is a prominent entity in the German cannabis market, primarily offering products and services related to both medical and recreational cannabis use. Their core offerings include licensed dispensaries that provide cannabis products through scientifically monitored pilot projects located in cities like Berlin, Frankfurt, and Hanover. The company's dispensaries focus on regulated distribution and contribute to harm reduction research.

Furthermore, they have a significant operational presence in Switzerland, managing similar dispensaries there for over a year, catering to both adult consumers and healthcare professionals in urban markets. Sanity Group generates revenue through sales of cannabis products at its strategically located dispensaries in major urban areas. These transactions occur directly with consumers, allowing on-site purchases of licensed products. Partnerships with leading producers, such as Organigram Holdings Inc.

, bolster their supply chain and product offerings. Revenue streams are diversified, encompassing both medical and recreational cannabis sales, as well as potential collaborations with healthcare entities for research and pilot projects.